Laurus Labs Unaffected by Temporary Freeze on PEPFAR Funding

Laurus Labs, a prominent player in the ARV medicine market, has clarified its stance on the recent 90-day freeze on President's Emergency Plan for AIDS Relief (PEPFAR) funding programs. The company believes that any potential funding challenges will not significantly impact the procurement of medications, given that overall AIDS funding comes from various sources including country governments, PEPFAR, and the Global Fund. The recent decision of the USA to rejoin the WHO further reinforces this belief. No disclosure to stock exchanges is currently required.